Pharmaceuticals News and Research

RSS

81% of physicians visited Health Care Professional content websites in first-quarter 2010

comScore, Inc., a leader in measuring the digital world, and ImpactRx, a pharmaceutical insights company, today released the first in a series of reports from the comScore/ImpactRx Physician Behavioral Measurement™ solution, a unique digital measurement solution that measures physicians' actual online and mobile behaviors.

27 Aug 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

SYSPRO ERP solution support pharmaceutical manufacturers to new FDA regulation

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that the company is highly confident that the SYSPRO ERP solution will enable pharmaceutical manufacturers to meet the new U.S. Food and Drug Administration (FDA) regulations being proposed by Congress.

27 Aug 2010

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Neuroscientists in the Down Syndrome Research Group at the University of Arizona have created a battery of tests that quickly aid in the assessment of the cognitive abilities of persons with Down syndrome.

27 Aug 2010

Scientist finds man-made chemical enzyme to neutralize toxin

For the first time ever, a completely man-made chemical enzyme has been successfully used to neutralise a toxin found naturally in fruits and vegetables. While studying for her PhD in chemistry at the University of Copenhagen Dr. Jeannette Bjerre showed how a novel so called chemzyme was able to decompose glycoside esculin, a toxin found in horse-chestnuts.

27 Aug 2010

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Vanda Pharmaceuticals Inc., today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.

26 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010.

26 Aug 2010

Laxai Pharma reports $1,735K revenue for first six months

Laxai Pharma, Ltd. an international pharmaceutical contract research organization ("CRO"), is pleased to announce that it has published its second quarter results last week for the period ended as of June 30, 2010.

26 Aug 2010

AARP Report finds increase in brand-name drug costs outstrips inflation

"Retail prices for some of the most widely used brand-name prescription drugs shot up more than 8 percent in 2009, even as inflation plummeted to a record low, according to a new AARP analysis of retail drug price trends released today.

26 Aug 2010

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

26 Aug 2010

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for various forms of cancer and other diseases, today announced its second quarter 2010 financial results.

26 Aug 2010

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure.

26 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

Momenta Pharmaceuticals provides update on generic Lovenox litigation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC's request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the Company's collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generic version of Lovenox®. The decision is subject to appeal.

26 Aug 2010

Patterson first-quarter net income increases 20% to $53.93 million

Patterson Companies, Inc. today reported consolidated sales of $849,787,000 for the first quarter of fiscal 2011 ended July 31, an increase of 8% from $789,579,000 in the year-earlier quarter. Sales for the current quarter included the impact of an extra or fourteenth week, which will make fiscal 2011 a 53-week year ending on April 30, 2011. Net income of $53,925,000 or $0.45 per diluted share rose 20% from $45,057,000 or $0.38 per diluted share in the first quarter of fiscal 2010.

26 Aug 2010

PCMA reports increase in retail prices of popular brand-name drugs

The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new AARP report that examined retail prices of brand-name drugs and found that the 217 products most used by seniors increased by an average of 8.3 percent during 2009, while over the last five years retail prices for the most popular brand-name drugs increased 41.5 percent:

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

Pharmaceuticals News and Research

81% of physicians visited Health Care Professional content websites in first-quarter 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

SYSPRO ERP solution support pharmaceutical manufacturers to new FDA regulation

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Scientist finds man-made chemical enzyme to neutralize toxin

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

Aethlon Medical receives approval for Chronic HCV Infection treatment

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Laxai Pharma reports $1,735K revenue for first six months

AARP Report finds increase in brand-name drug costs outstrips inflation

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

NeoPharm second-quarter net loss decreases to $0.8 million

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Momenta Pharmaceuticals provides update on generic Lovenox litigation

Patterson first-quarter net income increases 20% to $53.93 million

PCMA reports increase in retail prices of popular brand-name drugs

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence